Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284461 | 0.86 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL2511405 | 0.81 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL12284589 | 0.81 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL14321194 | 0.80 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL12284571 | 0.79 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL2511731 | 0.79 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL12264875 | 0.79 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL2552088 | 0.78 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL2549925 | 0.77 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL2510656 | 0.77 | CNR2 (0.56) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552916-B1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | LILLY CO ELI (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2552916-B1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | LILLY CO ELI (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8710063-B2 | Purine compounds used as CB2 agonists | ELI LILLY AND COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2552916-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | Eli Lilly and Company (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| CN-102803263-A | Purine compounds useful as CB2 agonists | LILLY CO ELI | 2012-11-28 | — | — | CN | disclosed |
| WO-2011123482-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123482-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | ELI LILLY AND COMPANY (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329809-A1 | PURINE COMPOUNDS USED AS CB2 AGONISTS | CNR2, CNR1, P2RX7 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.